Toceranib

Toceranib
Clinical data
Trade names	Palladia
AHFS/Drugs.com	Veterinary Use
License data	US DailyMed: Toceranib;
Routes of; administration	By mouth
Drug class	Antineoplastic agent
ATCvet code	QL01EX90 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	77%
Protein binding	91%-93%
Elimination half-life	16 h
Identifiers
	IUPAC name 5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide;
CAS Number	356068-94-5; as salt: 874819-74-6;
PubChem CID	5329106; as salt: 16034840;
ChemSpider	4486268; as salt: 13163443;
UNII	59L7Y0530C; as salt: 24F9PF7J3R;
KEGG	D08503; as salt: D08544;
ChEMBL	ChEMBL13608; as salt: ChEMBL2103833;
PDB ligand	BWC (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID50189076 ;
Chemical and physical data
Formula	C22H25FN4O2
Molar mass	396.466 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc2c(c1)/C(C(=O)N2)=C/c4c(c(C(=O)NCCN3CCCC3)c([nH]4)C)C;
	InChI InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-; Key:SRSGVKWWVXWSJT-ATVHPVEESA-N;

Toceranib (INN), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma. It is the first medication developed specifically for the treatment of cancer in dogs. It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.

The most common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss, and blood in the stool.